Details of the Drug Combination

General Information of Drug Combination (ID: DCU31H5)

• Drug Combination Name: BIIB-098 + FP-187
• Indication: Multiple Sclerosis; Status: Phase 1 [1]
• Component Drugs:
  BIIB-098 (DMOOCCN): N.A.
  FP-187 (DMWZO21): N.A.

References

• [1] ClinicalTrials.gov (NCT05767736) A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [4] ClinicalTrials.gov (NCT01230138) Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis. U.S. National Institutes of Health.